Anti-IL23α (Mirikizumab), Humanized Antibody

• Data sheet: View or download

The research-grade biosimilar is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23 but does not bind to IL12. IL-23 is expressed and secreted by dendritic cells and macrophages. It belongs to the family of IL-12 cytokines and has two subunits: p40 that is shared with IL-12 and p19 that is unique for IL-23. IL-23 plays a critical role in maintaining and expanding Th17 cells. It also stimulates multiple innate immune cells such as myeloid cells and NK cells to produce proinflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases such as Ulcerative Colitis (UC). By binding to the p19 subunit of IL-23, the antibody inhibits the release of proinflammatory cytokines and reduces the inflammatory response. The original drug is currently undergoing clinical trials to treat moderate-to-severe UC, psoriasis, and Crohn’s disease